Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fosinoprilat is the active metabolite of fosinopril, an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension and heart failure. Fosinopril itself is a prodrug that is rapidly hydrolyzed in the body to form fosinoprilat, which exerts its pharmacological effects. Fosinoprilat acts as a competitive inhibitor of ACE, blocking the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor involved in blood pressure regulation and aldosterone secretion. By inhibiting this pathway, fosinoprilat reduces peripheral vascular resistance and lowers blood pressure, while also decreasing afterload on the heart in patients with heart failure[3][5][6]. Unlike some other ACE inhibitors that are eliminated primarily by renal excretion, both renal and hepatic pathways contribute to elimination of fosinopril/fosinoprilat[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fosinoprilat.